New preclinical findings suggest boosting nad+ with niagen® holds potential for slowing aging process and reducing metabolic damage

Chromadex corp. (nasdaq:cdxc) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of niagen® (n

CZR Ratings Summary

CZR Quant Ranking